India to Expand Import Clearance Points for Pharma and Medical Devices

The Union Ministry of Health and Family Welfare in India is moving forward with plans to broaden the list of authorised locations where drugs, medical devices, and cosmetics can be imported and cleared. This initiative aims to enhance the efficiency of the import process and strengthen the supply chain for healthcare products across the country.

On Tuesday, the ministry unveiled a draft notification proposing amendments to Rule 43A of the Drugs Rules, 1945. This rule currently governs the designated ports, airports, railway stations, roadways, and other entry points authorised for pharmaceutical imports. The proposed changes would expand the network to include seven additional inland container depots (ICDs), one special economic zone (SEZ), and a new international airport.

The draft lists the inclusion of ICDs located in Sonipat, Piala, and Garhi Harsaru in Haryana; Dadri in Uttar Pradesh; Mundra in Gujarat; Sanathnagar and Thimmapur in Hyderabad; and Whitefield in Bengaluru. At present, only two ICDs, Dhannad and Tihi near Indore, are on the approved list. The Bommasandra SEZ in Karnataka is also proposed to be added, alongside the Noida International Airport at Jewar in Uttar Pradesh. Once approved, Jewar will become the fourth airport authorised for pharmaceutical imports after Cochin, Thiruvananthapuram, and Navi Mumbai.

Officials familiar with the proposal explained that this expansion is designed to simplify the import clearance process and improve logistics efficiency. By enabling importers to receive consignments closer to their manufacturing plants, warehouses, and distribution centers, transportation distances within the country can be significantly reduced. This change is expected to lower logistics costs and help avoid delays in the movement of imported healthcare goods.

The ministry has invited feedback from stakeholders and industry participants, offering a 30-day window from the publication date of the draft notification for submitting objections and suggestions.

The Medical Technology Association of India (MTaI) welcomed the proposal, highlighting its likely benefits. The association pointed out that allowing customs clearance nearer to major healthcare and distribution hubs can reduce logistical expenses and minimize delays, which is crucial for medical technologies. Timely availability of such products can have a direct impact on patient care, making efficient supply chains essential.

India’s pharmaceutical and medical device industry plays a critical role in the global healthcare ecosystem. The country is a major supplier of generic medicines worldwide and has a rapidly growing domestic healthcare market. Improving the infrastructure and regulatory framework for imports aligns with broader government efforts to boost manufacturing and supply chain resilience under initiatives like Make in India.

With increasing demand for quality healthcare products, especially following the Covid-19 pandemic, streamlining import channels is a strategic move. It helps manufacturers and suppliers respond quickly to market needs, ensuring that essential medicines and medical devices reach hospitals, clinics, and pharmacies without unnecessary delay.

This expansion of authorised import gateways reflects the government’s commitment to supporting the healthcare sector by addressing logistical challenges and fostering a more responsive import system. If implemented, the new facilities will enhance the overall efficiency of the pharmaceutical supply chain and contribute to better healthcare service delivery across India.